Published in Radiat Oncol J on March 31, 2013
Current status of IMRT in head and neck cancer. Rep Pract Oncol Radiother (2013) 0.85
The Role of Neoadjuvant Chemotherapy in the Treatment of Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Study (KROG 11-06) Using Propensity Score Matching Analysis. Cancer Res Treat (2015) 0.85
Evaluation of a commercial orthopaedic metal artefact reduction tool in radiation therapy of patients with head and neck cancer. Br J Radiol (2015) 0.76
Helical tomotherapy in head and neck cancer: a European single-center experience. Oncologist (2015) 0.75
The effect of clove-based herbal mouthwash on radiation-induced oral mucositis in patients with head and neck cancer: a single-blind randomized preliminary study. Onco Targets Ther (2016) 0.75
Volumetric modulated arc radiotherapy of the whole larynx, followed by a single affected vocal cord, for T1a glottic cancer: Dosimetric analysis of a case. Mol Clin Oncol (2016) 0.75
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol (2011) 7.46
The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol (1989) 5.78
Tomotherapy: a new concept for the delivery of dynamic conformal radiotherapy. Med Phys (1994) 4.50
Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2003) 2.95
A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys (2001) 2.85
Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys (2003) 2.29
Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program. Int J Radiat Oncol Biol Phys (2008) 2.13
Patterns of local-regional recurrence following parotid-sparing conformal and segmental intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys (2000) 1.83
Quality of life and survival outcome for patients with nasopharyngeal carcinoma receiving three-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy-a longitudinal study. Int J Radiat Oncol Biol Phys (2008) 1.64
Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol (2001) 1.51
The potential for sparing of parotids and escalation of biologically effective dose with intensity-modulated radiation treatments of head and neck cancers: a treatment design study. Int J Radiat Oncol Biol Phys (2000) 1.38
Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience. Int J Radiat Oncol Biol Phys (2005) 1.25
Intensity-modulated radiation therapy in head and neck cancers: The Mallinckrodt experience. Int J Cancer (2000) 1.23
Significant improvement in normal tissue sparing and target coverage for head and neck cancer by means of helical tomotherapy. Radiother Oncol (2006) 1.18
Intensity-modulated radiation therapy (IMRT) dosimetry of the head and neck: a comparison of treatment plans using linear accelerator-based IMRT and helical tomotherapy. Int J Radiat Oncol Biol Phys (2006) 1.15
Radiobiological basis and clinical results of the simultaneous integrated boost (SIB) in intensity modulated radiotherapy (IMRT) for head and neck cancer: A review. Crit Rev Oncol Hematol (2009) 1.10
Intensity-modulated radiotherapy in head and neck cancer: results of the prospective study GORTEC 2004-03. Radiother Oncol (2012) 1.10
Comparison between conventional and intensity-modulated post-operative radiotherapy for stage III and IV oral cavity cancer in terms of treatment results and toxicity. Oral Oncol (2008) 1.09
Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: the University of Wisconsin experience. Head Neck (2010) 0.98
Health-related quality-of-life outcomes following IMRT versus conventional radiotherapy for oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys (2007) 0.96
Simultaneous integrated boost using intensity-modulated radiotherapy compared with conventional radiotherapy in patients treated with concurrent carboplatin and 5-fluorouracil for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys (2011) 0.96
Intensity-modulated radiotherapy improves target coverage, spinal cord sparing and allows dose escalation in patients with locally advanced cancer of the larynx. Radiother Oncol (2004) 0.92
Initial clinical experience with helical tomotherapy for head and neck cancer. Head Neck (2009) 0.91
Intensity-modulated radiotherapy in patients with head and neck cancer: a European single-centre experience. Br J Radiol (2011) 0.89
Patterns of care and outcomes associated with intensity-modulated radiation therapy versus conventional radiation therapy for older patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys (2012) 0.87
The role of intensity modulated radiotherapy in advanced oral cavity carcinoma. J Cancer Res Ther (2012) 0.87
Improved dosimetric and clinical outcomes with intensity-modulated radiotherapy for head-and-neck cancer of unknown primary origin. Int J Radiat Oncol Biol Phys (2010) 0.84
Intensity-modulated radiotherapy for cervical lymph node metastases from unknown primary cancer. Int J Radiat Oncol Biol Phys (2008) 0.83
Prognostic factors in head-and-neck cancer patients treated with surgery followed by intensity-modulated radiotherapy (IMRT), 3D-conformal radiotherapy, or conventional radiotherapy. Oral Oncol (2006) 0.82
Preoperative concurrent chemoradiotherapy for locally advanced rectal cancer: treatment outcomes and analysis of prognostic factors. Cancer Res Treat (2012) 0.93
Treatment outcomes of helical intensity-modulated radiotherapy for unresectable hepatocellular carcinoma. Gut Liver (2013) 0.90
Which patients might benefit from postmastectomy radiotherapy in breast cancer patients with t1-2 tumor and 1-3 axillary lymph nodes metastasis? Cancer Res Treat (2013) 0.87
Topical use of recombinant human epidermal growth factor (EGF)-based cream to prevent radiation dermatitis in breast cancer patients: a single-blind randomized preliminary study. Asian Pac J Cancer Prev (2013) 0.85
Low dose radiation overcomes diabetes-induced suppression of hippocampal neuronal cell proliferation in rats. J Korean Med Sci (2006) 0.84
Adaptive responses induced by low dose radiation in dentate gyrus of rats. J Korean Med Sci (2006) 0.80
Clinical outcome of helical tomotherapy for inoperable non- small cell lung cancer: the Kyung Hee University Medical Center experience. Asian Pac J Cancer Prev (2014) 0.79
The application of the Six Sigma program for the quality management of the PACS. AJR Am J Roentgenol (2005) 0.79
Optimal follow-up duration for evaluating objective response to radiotherapy in patients with hepatocellular carcinoma: a retrospective study. Chin J Cancer (2014) 0.77
A long term results of external beam radiation therapy in hemophilic arthropathy of the ankle in children. J Korean Med Sci (2010) 0.75
Role of radiotherapy for pancreatobiliary neuroendocrine tumors. Radiat Oncol J (2013) 0.75
Clinical Implications of VEGF and p53 Expression in Squamous Cell Carcinoma of the Cervix Treated with Radiation Therapy. Cancer Res Treat (2003) 0.75
Predictive factors for supraclavicular lymph node recurrence in N1 breast cancer patients. Asian Pac J Cancer Prev (2013) 0.75